Solvonis, an emerging biopharmaceutical company focused on high-burden CNS disorders, has received a Notice of Allowance from the USPTO covering a novel series of compounds in its proprietary SVN-SDN-14 Post Traumatic Stress Disorder (PTSD) discovery programme, further strengthening the programme’s IP position as it progresses toward lead-candidate selection, which remains on track for Q1 2026. The newly allowed claims protect serotonin (SERT), dopamine (DAT) and noradrenaline (NET) modulators engineered to address key historical limitations in PTSD drug developmentnamely duration control, inter-patient variability and real-world scalabilityby introducing predictable metabolic deactivation intended to improve dosing flexibility, safety margins and clinical suitability while retaining the therapeutic activity underpinning the approach. Importantly, the USPTO examiner determined that the claimed compounds were not disclosed or suggested by prior patents or publications, supporting the novelty of Solvonis’ chemical strategy. Positive, but make n0 change to recommendation or PT.
